| E.1 Medical condition or disease under investigation |
| E.1.1 | Medical condition(s) being investigated |
| patients suffering from Amyotrophic Lateral Sclerosis (ALS) |
|
| E.1.1.1 | Medical condition in easily understood language |
| Amyotrophic Lateral Sclerosis (ALS) |
|
| E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
| MedDRA Classification |
| E.1.2 Medical condition or disease under investigation |
| E.1.2 | Version | 21.1 |
| E.1.2 | Level | PT |
| E.1.2 | Classification code | 10002026 |
| E.1.2 | Term | Amyotrophic lateral sclerosis |
| E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
| E.1.3 | Condition being studied is a rare disease | No |
| E.2 Objective of the trial |
| E.2.1 | Main objective of the trial |
| The primary objective is to demonstrate statistically significant improvement from baseline in ALSFRS-R after 48-week treatment of two doses of masitinib versus matching placebo in patients diagnosed with ALS treated with Riluzole. |
|
| E.2.2 | Secondary objectives of the trial |
Secondary objectives are to assess the efficacy and safety of two doses of masitinib versus matching placebo in the treatment of patients diagnosed with ALS treated with Riluzole
|
|
| E.2.3 | Trial contains a sub-study | Yes |
| E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Pharmacodynamic/biomarker(s):
Identification of pharmacodynamic biomarker(s) is needed to fully characterize the potential disease modifying effects of masitinib in ALS patients.
PharmacoGenomic (PG) study:
Determination of the genetic polymorphisms, including HLA polymorphisms that could be associated with an increased risk of masitinib-induced severe neutropenia and severe skin toxicity
PharmacoKinetic (PK) study:
Measurement of pharmacokinetic parameters of masitinib and Riluzole in up to 10 ALS patients per group and validate population PK model for masitinib
|
|
| E.3 | Principal inclusion criteria |
1. Patient, male or female, diagnosed with laboratory supported probable, clinically probable or definite ALS according to the World Federation of Neurology Revised El Escorial criteria [52]
2. Patient with a familial or sporadic ALS
3. Patient aged between 18 and 75 years old inclusive at screening
4. Patient treated with a stable dose of Riluzole (100 mg/day) for at least 12 weeks prior to baseline visit
5. Patient with an ALS disease duration from diagnosis no longer than 24 months at screening
6. Patient with an ALSFRS-R total score progression between onset of the disease and screening of
> 0.3 and <1.1 point/month
7. Patient with an ALSFRS-R total score decrease of ≥ 1 point between screening and baseline
8. Patient with an ALSFRS-R total score of at least 26 at screening following rules below:
- at least 3 on item #3 and
- at least 2 on each of the other 11 items (i.e. item #1, #2, #4, #5a or #5b, #6, #7, #8, #9, #10, #11 and #12)
9. Patient with an ALSFRS-R total score of at least 25 at randomization following rules below:
- at least 3 on item #3 and
- at least 2 on each of the other 11 items (i.e. item #1, #2, #4, #5a or #5b, #6, #7, #8, #9, #10, #11 and #12)
10. Contraception:
- Female patient of childbearing potential (entering the study after a menstrual period and who has a negative pregnancy test), who agrees to use a highly effective method of contraception and an effective method of contraception by her male partner during the study and for 3 months and a half after the last treatment intake
- Male patient with a female partner of childbearing potential who agrees to use a highly effective method of contraception and an effective method of contraception by his female partner during the study and for 3 months and a half after the last treatment intake OR who agrees to use an effective method of contraception and a highly effective method of contraception by his female partner during the study and for 3 months and a half after the last treatment intake
Highly effective and effective methods of contraception are detailed in appendix 15.1
11. Patient able to understand, and willing to sign, and date the written informed consent form prior to any protocol-specific procedures. If patients are duly capable of study consent but are unable to sign by themselves due to aggravation of disease condition, written informed consent can be obtained from a legally authorized representative who can sign on behalf of the patients after confirming the patients' agreement to study participation.
12. Patient able and willing to comply with study protocol and to come on-site as per protocol visits schedule
13. Patient able to understand, and willing to follow the safety procedures mentioned on the patient card in case of signs or symptoms of severe neutropenia or severe cutaneous toxicity
|
|
| E.4 | Principal exclusion criteria |
1. Patient with dementia or significant neurological, psychiatric, systemic or organic disease, uncontrolled or that may interfere with the conduct of the trial or its results
2. Patient with hypersensitivity to masitinib or its excipients and riluzole or its excipients
3. Patient with an FVC < 60% predicted normal value for gender, height, and age at screening
4. Patient with a weight < 41 kg and a BMI < 21 or > 30 kg/m² at screening and at baseline
5. Pregnant, or nursing female patient
6. Patient with history (or family history) of severe skin toxicities or reactions
7. Patients treated by drugs known to be at high risk for Stevens-Johnson Syndrome or for Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome
8. Patient with history of severe bone marrow disorders such as agranulocytosis or aplasia, or with abnormal laboratory results from local laboratory assessments at screening and baseline :
- Neutropenia with ANC < 1.5x109/L
- Anemia with Hgb < LLN or red blood cell count below the LLN
- Thrombocytopenia with platelets counts < 150 x 109/L
9. Patient with history of hepatic disorders, with a known liver disease or alcohol abuse, or with abnormal laboratory results from local laboratory assessments defined as:
- hepatic transaminase levels > 2 ULN at baseline, or
- total bilirubin level > 1.5 ULN at baseline, or
- both hepatic transaminase levels and total bilirubin level outside of the normal ranges at screening and baseline, or
- albuminemia < 1 x LLN at screening and baseline
10. Patient with pre-existing severe renal impairment, or with abnormal laboratory results from local laboratory assessments at screening and baseline :
- Creatinine clearance < 60 mL/min (Cockcroft and Gault formula) or
- Proteinuria > 30 mg/dL (1+) on dipstick; in case of the proteinuria ≥ 1+ on the dipstick, 24 hours proteinuria must be > 1.5g/24 hours
11. Patient with active severe infection such as herpes, tuberculosis, viral hepatitis, human immunodeficiency virus infection
12. Patient with autoimmune conditions such as systemic lupus erythematosus
13. Patient with a diagnosis of cancer or evidence of continued disease within five years before screening
14. Patient with severe cardiac conditions:
- Patient with recent history (within the past 12 months) of severe cardiovascular conditions including acute myocardial infarction, unstable angina pectoris, coronary revascularization procedure, congestive heart failure of NYHA Class III or IV, stroke, including a transient ischemic attack
- Patient with cardiac conduction abnormalities at study entry including a QTc Fredericia interval >450 milliseconds for males and >470 milliseconds for females, a second- or third-degree atrioventricular block not successfully treated with a pacemaker
- Patient presenting with edema of cardiac origin and left ventricular ejection fraction ≤ 50%
15. Patient with risk factors for sudden unexpected death of cardiovascular origin
16. Patient who has been exposed to an investigational treatment within 3 months or five half-lives of the investigational product, whichever is longer, before the screening visit
17. Patient who has been treated to Edaravone within 30 days prior to screening
18. Patient treated concomitantly with known inducers or inhibitors of CYP1A2, inhibitors of CYP2C8, strong inducer of CYP3A4, and substrate of CYP3A4 with narrow therapeutic index. (see § 7.4.5 of IB)
19. Subjects with a significant pulmonary disorder not attributed to ALS or who require treatments that might complicate the evaluation of the effect of ALS on respiratory function
20. Previous participation in an earlier study with masitinib
21. Any medical condition that, in the opinion of the Investigator, might interfere with the patient’s participation in the trial, poses any added risk for the patient, or confounds the assessment of the patient.
22. Patient under psychiatric, patient protected by law under guardianship or curatorship, patient in emergency situations, prisoners and patient without National health insurance
|
|
| E.5 End points |
| E.5.1 | Primary end point(s) |
Absolute Change from baseline to week 48 in Amyotrophic Lateral Sclerosis functional rating scale (ALSFRS)-Revised total score
|
|
| E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
| E.5.2 | Secondary end point(s) |
- Progression free survival (PFS) defined as the time from randomization to progression (decline of more than 9 points in ALSFRS-R score from baseline) or death
- Amyotrophic Lateral Sclerosis Assessment Questionnaire 40 (ALSAQ-40) change
- Forced Vital Capacity (FVC) change
- Upper- and lower-limb muscle strength using hand-held dynamometry (HHD)
- Clinician-rated Clinical Global Impression (CGI)
- Combined Assessment of Function and Survival (CAFS)
- Overall Survival (OS)
- Event free survival (EFS) defined as the time from randomization to the first occurrence of either death or tracheostomy
Safety Analysis:
- Adverse events
- Vital signs, physical examination, ECGs
- Clinical laboratory tests (haematology, biochemistry, urinalysis and urinary cytology)
|
|
| E.5.2.1 | Timepoint(s) of evaluation of this end point |
| at W48 or event occurence (death) depending on secondary endpoint |
|
| E.6 and E.7 Scope of the trial |
| E.6 | Scope of the trial |
| E.6.1 | Diagnosis | No |
| E.6.2 | Prophylaxis | No |
| E.6.3 | Therapy | Yes |
| E.6.4 | Safety | Yes |
| E.6.5 | Efficacy | Yes |
| E.6.6 | Pharmacokinetic | Yes |
| E.6.7 | Pharmacodynamic | Yes |
| E.6.8 | Bioequivalence | No |
| E.6.9 | Dose response | No |
| E.6.10 | Pharmacogenetic | No |
| E.6.11 | Pharmacogenomic | Yes |
| E.6.12 | Pharmacoeconomic | No |
| E.6.13 | Others | No |
| E.7 | Trial type and phase |
| E.7.1 | Human pharmacology (Phase I) | No |
| E.7.1.1 | First administration to humans | No |
| E.7.1.2 | Bioequivalence study | No |
| E.7.1.3 | Other | No |
| E.7.1.3.1 | Other trial type description | |
| E.7.2 | Therapeutic exploratory (Phase II) | No |
| E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
| E.7.4 | Therapeutic use (Phase IV) | No |
| E.8 Design of the trial |
| E.8.1 | Controlled | Yes |
| E.8.1.1 | Randomised | Yes |
| E.8.1.2 | Open | No |
| E.8.1.3 | Single blind | No |
| E.8.1.4 | Double blind | Yes |
| E.8.1.5 | Parallel group | Yes |
| E.8.1.6 | Cross over | No |
| E.8.1.7 | Other | No |
| E.8.2 | Comparator of controlled trial |
| E.8.2.1 | Other medicinal product(s) | Yes |
| E.8.2.2 | Placebo | Yes |
| E.8.2.3 | Other | No |
| E.8.2.4 | Number of treatment arms in the trial | 3 |
| E.8.3 |
The trial involves single site in the Member State concerned
| No |
| E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
| E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
| E.8.5 | The trial involves multiple Member States | Yes |
| E.8.5.1 | Number of sites anticipated in the EEA | 29 |
| E.8.6 Trial involving sites outside the EEA |
| E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
| E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
| E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
| Argentina |
| Austria |
| Belgium |
| Canada |
| Denmark |
| France |
| Germany |
| Ireland |
| Israel |
| Italy |
| Netherlands |
| Poland |
| Portugal |
| Russian Federation |
| Slovenia |
| Spain |
| Sweden |
| Ukraine |
| United Kingdom |
| United States |
|
| E.8.7 | Trial has a data monitoring committee | Yes |
| E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
| E.8.9 Initial estimate of the duration of the trial |
| E.8.9.1 | In the Member State concerned years | 2 |
| E.8.9.1 | In the Member State concerned months | 0 |
| E.8.9.1 | In the Member State concerned days | 0 |
| E.8.9.2 | In all countries concerned by the trial years | 2 |
| E.8.9.2 | In all countries concerned by the trial months | 0 |
| E.8.9.2 | In all countries concerned by the trial days | 0 |
Print
